GARDP and FIND part of ARC Research Hub on AMR

[Geneva – 19 August 2019] 

GARDP and FIND welcome the Australian Minister for Education’s announcement of $5m to establish an Australian Research Council (ARC) Research Hub to Combat Antimicrobial Resistance, which will be led by the Kirby Institute.

GARDP announces ‘5 BY 25’ goal in response to the growing burden of antibiotic resistant infections

[Geneva – 26 June 2019] 

GARDP calls upon the global community to work with it to develop and deliver 5 new treatments by 2025 to address the most urgent public health needs

Today GARDP announces its ‘5 BY 25’ goal to deliver five new treatments in response to the growing global threat of antimicrobial resistance (AMR). GARDP’s five treatments will focus on the priority bacterial pathogens identified by the World Health Organization (WHO).

GARDP set up as independent legal entity

[Geneva – 2 April 2019]

GARDP is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun working with partners to develop antibiotics to tackle drug-resistant infections which pose a threat to global health and development, including the achievement of the Sustainable Development Goals.

GARDP and Evotec announce new partnership to discover novel antibiotics

[Geneva/Hamburg – 19 March 2019]

GARDP and Evotec AG are announcing the formation of a new strategic public-private partnership to tackle the growing threat of antimicrobial resistance (AMR). By joining forces, Evotec and GARDP will leverage their capabilities and networks to address drug-resistant bacterial infections.

GARDP and Penta partner to accelerate the development of children’s antibiotics to tackle AMR

[Geneva/Padova – 4 March 2019] 

GARDP and Penta, the paediatric infectious diseases research network, have joined forces to tackle drug-resistant infections in children. The strategic collaboration aims to accelerate paediatric development of antibiotic treatments including: clinical trials designed to meet regulatory requirements; and trials with a focus on public health interventions to inform treatment guidelines.

German MOH continues supporting GARDP’s efforts to develop affordable antibiotics

[Geneva – 4 January 2019]
Funding supports developing antibiotics for important global health priorities
GARDP is pleased to receive a EUR 1.5 million investment from the German Federal Ministry of Health (MOH). This funding is already contributing to GARDP’s efforts to develop antibiotics for drug-resistant infections including sexually-transmitted infections and newborns with sepsis – both important global health priorities. The investment also supports GARDP’s growth as its incubation period, hosted by DNDi, comes to an end.